{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T06:20:08Z","timestamp":1783059608920,"version":"3.54.6"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T00:00:00Z","timestamp":1575244800000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008594","name":"European Hematology Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008594","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["21198"],"award-info":[{"award-number":["21198"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001823","name":"Ministerstvo \u0160kolstv\u00ed, Ml\u00e1de\u017ee a T\u011blov\u00fdchovy","doi-asserted-by":"publisher","award":["CEITEC2020 LQ1601"],"award-info":[{"award-number":["CEITEC2020 LQ1601"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["AEGLE"],"award-info":[{"award-number":["AEGLE"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"name":"General Secretatiat for research and technology of Greece","award":["KRIPIS"],"award-info":[{"award-number":["KRIPIS"]}]},{"name":"ERA-NET TRANSCAN-2 JTC 2014, GCH-CLL","award":["143"],"award-info":[{"award-number":["143"]}]},{"name":"MIUR-PRIN","award":["2015ZMRFEA"],"award-info":[{"award-number":["2015ZMRFEA"]}]},{"name":"Swedish Cancer Society","award":["Swedish Cancer Society"],"award-info":[{"award-number":["Swedish Cancer Society"]}]},{"DOI":"10.13039\/501100004063","name":"Knut och Alice Wallenbergs Stiftelse","doi-asserted-by":"crossref","award":["Knut och Alice Wallenbergs Stiftelse (SE)"],"award-info":[{"award-number":["Knut och Alice Wallenbergs Stiftelse (SE)"]}],"id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","award":["Swedish Research Council"],"award-info":[{"award-number":["Swedish Research Council"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100007232","name":"Radiumhemmets Forskningsfonder","doi-asserted-by":"publisher","award":["Radiumhemmets Forskningsfonder"],"award-info":[{"award-number":["Radiumhemmets Forskningsfonder"]}],"id":[{"id":"10.13039\/501100007232","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Lion\u2019s Cancer Research Foundation","award":["Lion\u2019s Cancer Research Foundation"],"award-info":[{"award-number":["Lion\u2019s Cancer Research Foundation"]}]},{"name":"Marcus Borgstr\u00f6m\u2019s Foundatio","award":["Marcus Borgstr\u00f6m\u2019s Foundatio"],"award-info":[{"award-number":["Marcus Borgstr\u00f6m\u2019s Foundatio"]}]},{"name":"Selander\u2019s Foundation","award":["Selander\u2019s Foundation"],"award-info":[{"award-number":["Selander\u2019s Foundation"]}]},{"name":"State of scholarships foundation of Greece","award":["fellowship"],"award-info":[{"award-number":["fellowship"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>In order to gain insight into the contribution of DNA methylation to disease progression of chronic lymphocytic leukemia (CLL), using 450K Illumina arrays, we determined the DNA methylation profiles in paired pre-treatment\/relapse samples from 34 CLL patients treated with chemoimmunotherapy, mostly (<jats:italic>n<\/jats:italic>= 31) with the fludarabine-cyclophosphamide-rituximab (FCR) regimen.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The extent of identified changes in CLL cells versus memory B cells from healthy donors was termed \u201cepigenetic burden\u201d (EB) whereas the number of changes between the pre-treatment versus the relapse sample was termed \u201crelapse changes\u201d (RC). Significant (<jats:italic>p<\/jats:italic>&lt; 0.05) associations were identified between (i) high EB and short time-to-first-treatment (TTFT); and, (ii) few RCs and short time-to-relapse. Both the EB and the RC clustered in specific genomic regions and chromatin states, including regulatory regions containing binding sites of transcription factors implicated in B cell and CLL biology.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Overall, we show that DNA methylation in CLL follows different dynamics in response to chemoimmunotherapy. These epigenetic alterations were linked with specific clinical and biological features.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13148-019-0783-1","type":"journal-article","created":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T17:04:07Z","timestamp":1575306247000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["DNA methylation profiles in chronic lymphocytic leukemia patients treated with chemoimmunotherapy"],"prefix":"10.1186","volume":"11","author":[{"given":"Maria","family":"Tsagiopoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikos","family":"Papakonstantinou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodoros","family":"Moysiadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Mansouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Ljungstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart\u00ed","family":"Duran-Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andigoni","family":"Malousi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana C.","family":"Queir\u00f3s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla","family":"Plevova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujata","family":"Bhoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagoula","family":"Kollia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Oscier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achilles","family":"Anagnostopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livio","family":"Trentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Ritgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarka","family":"Pospisilova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niki","family":"Stavroyianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Ghia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose I.","family":"Martin-Subero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Pott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Rosenquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8529-640X","authenticated-orcid":false,"given":"Kostas","family":"Stamatopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,2]]},"reference":[{"key":"783_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2018.02.001","volume":"51","author":"L Mansouri","year":"2018","unstructured":"Mansouri L, Wierzbinska JA, Plass C, Rosenquist R. Epigenetic deregulation in chronic lymphocytic leukemia: clinical and biological impact. Semin Cancer Biol. 2018;51:1\u201311.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"783_CR2","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/leu.2012.245","volume":"27","author":"N Cahill","year":"2013","unstructured":"Cahill N, Bergh AC, Kanduri M, Goransson-Kultima H, Mansouri L, Isaksson A, et al. 450\u2009K-array analysis of chronic lymphocytic leukemia cells reveals global DNA methylation to be relatively stable over time and similar in resting and proliferative compartments. Leukemia. 2013;27(1):150\u20138.","journal-title":"Leukemia."},{"issue":"3","key":"783_CR3","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/ng.3488","volume":"48","author":"CC Oakes","year":"2016","unstructured":"Oakes CC, Seifert M, Assenov Y, Gu L, Przekopowitz M, Ruppert AS, et al. DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia. Nat Genet. 2016;48(3):253\u201364.","journal-title":"Nat Genet"},{"issue":"3","key":"783_CR4","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1158\/2159-8290.CD-13-0349","volume":"4","author":"CC Oakes","year":"2014","unstructured":"Oakes CC, Claus R, Gu L, Assenov Y, Hullein J, Zucknick M, et al. Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia. Cancer Discov. 2014;4(3):348\u201361.","journal-title":"Cancer Discov."},{"key":"783_CR5","doi-asserted-by":"publisher","first-page":"e303","DOI":"10.1038\/bcj.2015.14","volume":"5","author":"EN Smith","year":"2015","unstructured":"Smith EN, Ghia EM, DeBoever CM, Rassenti LZ, Jepsen K, Yoon KA, et al. Genetic and epigenetic profiling of CLL disease progression reveals limited somatic evolution and suggests a relationship to memory-cell development. Blood Cancer J. 2015;5:e303.","journal-title":"Blood Cancer J."},{"issue":"9747","key":"783_CR6","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","volume":"376","author":"M Hallek","year":"2010","unstructured":"Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164\u201374.","journal-title":"Lancet."},{"issue":"16","key":"783_CR7","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1182\/blood-2015-05-647925","volume":"126","author":"D Rossi","year":"2015","unstructured":"Rossi D, Terzi-di-Bergamo L, De Paoli L, Cerri M, Ghilardi G, Chiarenza A, et al. Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. Blood. 2015;126(16):1921\u20134.","journal-title":"Blood."},{"issue":"3","key":"783_CR8","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1182\/blood-2015-09-667675","volume":"127","author":"PA Thompson","year":"2016","unstructured":"Thompson PA, Tam CS, O\u2019Brien SM, Wierda WG, Stingo F, Plunkett W, et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016;127(3):303\u20139.","journal-title":"Blood."},{"issue":"2","key":"783_CR9","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","volume":"127","author":"K Fischer","year":"2016","unstructured":"Fischer K, Bahlo J, Fink AM, Goede V, Herling CD, Cramer P, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127(2):208\u201315.","journal-title":"Blood."},{"issue":"18","key":"783_CR10","doi-asserted-by":"publisher","first-page":"4101","DOI":"10.1182\/blood-2011-11-312421","volume":"119","author":"T Zenz","year":"2012","unstructured":"Zenz T, Gribben JG, Hallek M, Dohner H, Keating MJ, Stilgenbauer S. Risk categories and refractory CLL in the era of chemoimmunotherapy. Blood. 2012;119(18):4101\u20137.","journal-title":"Blood."},{"key":"783_CR11","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1182\/asheducation-2010.1.481","volume":"2010","author":"S Stilgenbauer","year":"2010","unstructured":"Stilgenbauer S, Zenz T. Understanding and managing ultra high-risk chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2010;2010:481\u20138.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"783_CR12","doi-asserted-by":"crossref","unstructured":"Papakonstantinou N, Ntoufa S, Tsagiopoulou M, Moysiadis T, Bhoi S, Malousi A, et al. Integrated epigenomic and transcriptomic analysis reveals TP63 as a novel player in clinically aggressive chronic lymphocytic leukemia. Int J Cancer. 2018.","DOI":"10.1002\/ijc.31999"},{"issue":"8","key":"783_CR13","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1182\/blood.V80.8.2074.bloodjournal8082074","volume":"80","author":"J Wahlfors","year":"1992","unstructured":"Wahlfors J, Hiltunen H, Heinonen K, Hamalainen E, Alhonen L, Janne J. Genomic hypomethylation in human chronic lymphocytic leukemia. Blood. 1992;80(8):2074\u201380.","journal-title":"Blood."},{"issue":"11","key":"783_CR14","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1038\/ng.2443","volume":"44","author":"M Kulis","year":"2012","unstructured":"Kulis M, Heath S, Bibikova M, Queiros AC, Navarro A, Clot G, et al. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet. 2012;44(11):1236\u201342.","journal-title":"Nat Genet."},{"issue":"10","key":"783_CR15","doi-asserted-by":"publisher","first-page":"R115","DOI":"10.1186\/gb-2013-14-10-r115","volume":"14","author":"S Horvath","year":"2013","unstructured":"Horvath S. DNA methylation age of human tissues and cell types. Genome Biol. 2013;14(10):R115.","journal-title":"Genome Biol"},{"issue":"8","key":"783_CR16","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1182\/blood-2015-10-674572","volume":"127","author":"V Ljungstrom","year":"2016","unstructured":"Ljungstrom V, Cortese D, Young E, Pandzic T, Mansouri L, Plevova K, et al. Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations. Blood. 2016;127(8):1007\u201316.","journal-title":"Blood."},{"issue":"4","key":"783_CR17","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.cell.2013.01.019","volume":"152","author":"DA Landau","year":"2013","unstructured":"Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013;152(4):714\u201326.","journal-title":"Cell."},{"issue":"6","key":"783_CR18","doi-asserted-by":"publisher","first-page":"567","DOI":"10.4161\/epi.20237","volume":"7","author":"L Pei","year":"2012","unstructured":"Pei L, Choi JH, Liu J, Lee EJ, McCarthy B, Wilson JM, et al. Genome-wide DNA methylation analysis reveals novel epigenetic changes in chronic lymphocytic leukemia. Epigenetics. 2012;7(6):567\u201378.","journal-title":"Epigenetics."},{"issue":"2","key":"783_CR19","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2009-07-232868","volume":"115","author":"M Kanduri","year":"2010","unstructured":"Kanduri M, Cahill N, Goransson H, Enstrom C, Ryan F, Isaksson A, et al. Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia. Blood. 2010;115(2):296\u2013305.","journal-title":"Blood."},{"issue":"12","key":"783_CR20","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.4161\/epi.22901","volume":"7","author":"M Kanduri","year":"2012","unstructured":"Kanduri M, Marincevic M, Halldorsdottir AM, Mansouri L, Junevik K, Ntoufa S, et al. Distinct transcriptional control in major immunogenetic subsets of chronic lymphocytic leukemia exhibiting subset-biased global DNA methylation profiles. Epigenetics. 2012;7(12):1435\u201342.","journal-title":"Epigenetics."},{"issue":"3","key":"783_CR21","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/leu.2014.252","volume":"29","author":"AC Queiros","year":"2015","unstructured":"Queiros AC, Villamor N, Clot G, Martinez-Trillos A, Kulis M, Navarro A, et al. A B-cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact. Leukemia. 2015;29(3):598\u2013605.","journal-title":"Leukemia."},{"issue":"16","key":"783_CR22","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1182\/bloodadvances.2019000237","volume":"3","author":"TK Wojdacz","year":"2019","unstructured":"Wojdacz TK, Amarasinghe HE, Kadalayil L, Beattie A, Forster J, Blakemore SJ, et al. Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: results from 3 UK clinical trials. Blood Adv. 2019;3(16):2474\u201381.","journal-title":"Blood Adv."},{"issue":"6","key":"783_CR23","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.ccell.2014.10.012","volume":"26","author":"DA Landau","year":"2014","unstructured":"Landau DA, Clement K, Ziller MJ, Boyle P, Fan J, Gu H, et al. Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. Cancer Cell. 2014;26(6):813\u201325.","journal-title":"Cancer Cell."},{"issue":"4","key":"783_CR24","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1182\/blood-2015-02-585042","volume":"126","author":"R Guieze","year":"2015","unstructured":"Guieze R, Wu CJ. Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia. Blood. 2015;126(4):445\u201353.","journal-title":"Blood."},{"issue":"7","key":"783_CR25","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1038\/ng.3291","volume":"47","author":"M Kulis","year":"2015","unstructured":"Kulis M, Merkel A, Heath S, Queiros AC, Schuyler RP, Castellano G, et al. Whole-genome fingerprint of the DNA methylome during human B cell differentiation. Nat Genet. 2015;47(7):746\u201356.","journal-title":"Nat Genet."},{"issue":"5","key":"783_CR26","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.ccell.2016.09.014","volume":"30","author":"AC Queiros","year":"2016","unstructured":"Queiros AC, Beekman R, Vilarrasa-Blasi R, Duran-Ferrer M, Clot G, Merkel A, et al. Decoding the DNA methylome of mantle cell lymphoma in the light of the entire B cell lineage. Cancer Cell. 2016;30(5):806\u201321.","journal-title":"Cancer Cell."},{"issue":"1","key":"783_CR27","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/cdd.2017.185","volume":"25","author":"MP Kim","year":"2018","unstructured":"Kim MP, Lozano G. Mutant p53 partners in crime. Cell Death Differ. 2018;25(1):161\u20138.","journal-title":"Cell Death Differ"},{"issue":"2","key":"783_CR28","doi-asserted-by":"publisher","first-page":"188","DOI":"10.15252\/embr.201540488","volume":"17","author":"S Di Agostino","year":"2016","unstructured":"Di Agostino S, Sorrentino G, Ingallina E, Valenti F, Ferraiuolo M, Bicciato S, et al. YAP enhances the pro-proliferative transcriptional activity of mutant p53 proteins. EMBO Rep. 2016;17(2):188\u2013201.","journal-title":"EMBO Rep"},{"issue":"8","key":"783_CR29","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1593\/neo.13376","volume":"15","author":"X Huang","year":"2013","unstructured":"Huang X, Zhang Y, Tang Y, Butler N, Kim J, Guessous F, et al. A novel PTEN\/mutant p53\/c-Myc\/Bcl-XL axis mediates context-dependent oncogenic effects of PTEN with implications for cancer prognosis and therapy. Neoplasia. 2013;15(8):952\u201365.","journal-title":"Neoplasia."},{"issue":"4","key":"783_CR30","doi-asserted-by":"publisher","first-page":"164","DOI":"10.5808\/GI.2013.11.4.164","volume":"11","author":"JD Choi","year":"2013","unstructured":"Choi JD, Lee JS. Interplay between epigenetics and genetics in cancer. Genomics Inform. 2013;11(4):164\u201373.","journal-title":"Genomics Inform."},{"issue":"2","key":"783_CR31","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s13148-010-0017-z","volume":"2","author":"EL Putiri","year":"2011","unstructured":"Putiri EL, Robertson KD. Epigenetic mechanisms and genome stability. Clin Epigenet. 2011;2(2):299\u2013314.","journal-title":"Clin Epigenet"},{"issue":"7568","key":"783_CR32","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/nature15251","volume":"525","author":"J Zhu","year":"2015","unstructured":"Zhu J, Sammons MA, Donahue G, Dou Z, Vedadi M, Getlik M, et al. Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. Nature. 2015;525(7568):206\u201311.","journal-title":"Nature."},{"key":"783_CR33","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.semcancer.2017.08.008","volume":"51","author":"JI Martin-Subero","year":"2018","unstructured":"Martin-Subero JI, Oakes CC. Charting the dynamic epigenome during B-cell development. Semin Cancer Biol. 2018;51:139\u201348.","journal-title":"Semin Cancer Biol."},{"issue":"24","key":"783_CR34","doi-asserted-by":"publisher","first-page":"35946","DOI":"10.18632\/oncotarget.9371","volume":"7","author":"N Papakonstantinou","year":"2016","unstructured":"Papakonstantinou N, Ntoufa S, Chartomatsidou E, Kotta K, Agathangelidis A, Giassafaki L, et al. The histone methyltransferase EZH2 as a novel prosurvival factor in clinically aggressive chronic lymphocytic leukemia. Oncotarget. 2016;7(24):35946\u201359.","journal-title":"Oncotarget."},{"issue":"2","key":"783_CR35","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/ijc.31057","volume":"142","author":"C Wolf","year":"2018","unstructured":"Wolf C, Garding A, Filarsky K, Bahlo J, Robrecht S, Becker N, et al. NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib. Int J Cancer. 2018;142(2):322\u201333.","journal-title":"Int J Cancer."},{"issue":"6","key":"783_CR36","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41591-018-0028-4","volume":"24","author":"R Beekman","year":"2018","unstructured":"Beekman R, Chapaprieta V, Russinol N, Vilarrasa-Blasi R, Verdaguer-Dot N, Martens JHA, et al. The reference epigenome and regulatory chromatin landscape of chronic lymphocytic leukemia. Nat Med. 2018;24(6):868\u201380.","journal-title":"Nat Med."},{"issue":"7","key":"783_CR37","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1038\/leu.2016.359","volume":"31","author":"E Young","year":"2017","unstructured":"Young E, Noerenberg D, Mansouri L, Ljungstrom V, Frick M, Sutton LA, et al. EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia. Leukemia. 2017;31(7):1547\u201354.","journal-title":"Leukemia."},{"issue":"10","key":"783_CR38","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1038\/leu.2012.99","volume":"26","author":"I Molina-Privado","year":"2012","unstructured":"Molina-Privado I, Jimenez PR, Montes-Moreno S, Chiodo Y, Rodriguez-Martinez M, Sanchez-Verde L, et al. E2F4 plays a key role in Burkitt lymphoma tumorigenesis. Leukemia. 2012;26(10):2277\u201385.","journal-title":"Leukemia."},{"key":"783_CR39","doi-asserted-by":"crossref","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for diagnosis, indications for treatment, response assessment and supportive management of chronic lymphocytic leukemia. Blood. 2018.","DOI":"10.1182\/blood-2017-09-806398"},{"issue":"6","key":"783_CR40","doi-asserted-by":"publisher","first-page":"R44","DOI":"10.1186\/gb-2012-13-6-r44","volume":"13","author":"J Maksimovic","year":"2012","unstructured":"Maksimovic J, Gordon L, Oshlack A. SWAN: Subset-quantile within array normalization for illumina infinium HumanMethylation450 BeadChips. Genome Biol. 2012;13(6):R44.","journal-title":"Genome Biol"},{"issue":"3-4","key":"783_CR41","doi-asserted-by":"crossref","first-page":"25","DOI":"10.18632\/oncoscience.346","volume":"4","author":"M Duran-Ferrer","year":"2017","unstructured":"Duran-Ferrer M, Beekman R, Martin-Subero JI. In silico deconvolution and purification of cancer epigenomes. Oncoscience. 2017;4(3-4):25\u20136.","journal-title":"Oncoscience."},{"issue":"11","key":"783_CR42","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1084\/jem.194.11.1625","volume":"194","author":"U Klein","year":"2001","unstructured":"Klein U, Tu Y, Stolovitzky GA, Mattioli M, Cattoretti G, Husson H, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med. 2001;194(11):1625\u201338.","journal-title":"J Exp Med"},{"issue":"D1","key":"783_CR43","doi-asserted-by":"publisher","first-page":"D260","DOI":"10.1093\/nar\/gkx1126","volume":"46","author":"A Khan","year":"2018","unstructured":"Khan A, Fornes O, Stigliani A, Gheorghe M, Castro-Mondragon JA, van der Lee R, et al. JASPAR 2018: update of the open-access database of transcription factor binding profiles and its web framework. Nucleic Acids Res. 2018;46(D1):D260\u2013D6.","journal-title":"Nucleic Acids Res"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-019-0783-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13148-019-0783-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-019-0783-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T11:23:04Z","timestamp":1665141784000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-019-0783-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["783"],"URL":"https:\/\/doi.org\/10.1186\/s13148-019-0783-1","relation":{},"ISSN":["1868-7075","1868-7083"],"issn-type":[{"value":"1868-7075","type":"print"},{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"24 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the local Ethics Review Committee for the Institute of Applied Biosciences\/Centre for Research and Technology Hellas (Ref. No: ETH.COM-45).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PG has received research funding from AbbVie, Gilead, Janssen, Novartis, and Sunesis. Has received honoraria from AbbVie, Acerta, BeiGene, Gilead, Janssen, Novartis, and Sunesis. RR has received honoraria from AbbVie, Janssen, Illumina, and Roche. KS received research support from Janssen Pharmaceuticals and Roche SA. All other authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"177"}}